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Abstract
Background: Patients on dialysis often have secondary 
hyperparathyroidism (SHPT), a disorder associated with 
renal osteodystrophy, progressive vascular calcification, 
cardiovascular disease, and death. The objective of this 
retrospective observational study was to evaluate, in dialysis 
patients with SHPT, the impact of different levels of adherence 
to cinacalcet therapy on hospitalisations and direct healthcare 
costs charged to the Lombardy Regional Health Service (Italy).
Methods: Data recorded in the administrative databases on 
all citizens undergoing dialysis between 1 January 2011 and 31 
December 2011 were selected. For the aim of this study, patients 
with SHPT already on dialysis in the first 6 months of 2009 who 
had been treated with cinacalcet for at least 365 days were 
selected and retrospectively analysed through to end of 2012. 
Healthcare resource utilisation, cinacalcet adherence, and costs 
for medication, hospitalisations, and diagnostic/therapeutic 
procedures were estimated.
Results: A total of 994 patients were identified (mean age 
63.0 years, females 43.5%). The first patient tertile had an 
adherence to cinacalcet of <64.1%, whereas the third had an 
adherence of over 91.5%. Patients in the third adherence tertile 
experienced fewer all-causes hospitalisations than those in the 
first tertile (−19.2%; p=0.01423), fractures (−37.1%; p=0.59422), 
cardiovascular disease (−23.8%; p=0.04025), and sepsis (−32.3%; 
p=0.01386). The increase in costs for cinacalcet-adherent 
patients is almost completely offset by the reduction in costs 
for hospitalisations.
Conclusions: The results of the analysis suggest that there 
may be some correlation between a high level of cinacalcet 
adherence and a decrease in hospitalisations.
Keywords: cinacalcet, costs, dialysis, SHPT, therapeutic 
adherence.
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Introduction
Parathyroid hormone (PTH) plays a key role in the regulation 
of calcium-phosphorus metabolism, by maintaining normal 
bone processes along with the action of vitamin D. When 
kidney function is absent or impaired, this regulatory activity 
is compromised, resulting in high serum phosphorus and low 
serum calcium levels, and an increase in circulating PTH due 
to the repeated stimulation of the parathyroid glands, leading 
to the onset of secondary hyperparathyroidism (SHPT).1 SHPT, 
which is characterised by high serum PTH levels, parathyroid 
gland hyperplasia, and mineral metabolism disorders, primarily 
causes renal osteodystrophy and is associated with progressive 
vascular calcification (VC), and ultimately, cardiovascular (CV) 
disease and death, especially in patients with chronic kidney 
disease (CKD) receiving haemodialysis (HD). In the literature, 
this spectrum of disorders is jointly referred to as CKD-mineral 
and bone disease (CKD-MBD).2,3 Given their key roles in the 
pathogenesis of SHPT, calcium-sensing receptors (CaSR) and 
vitamin D receptors (VDR) are biologically plausible targets for 
emerging therapies for the treatment of this condition.4
Initially, classical therapy for SHPT in dialysed patients usually 
consists of calcium salts, intestinal phosphate binders, and 
active vitamin D metabolites. As this therapeutic approach is 
very rarely able to prevent PTH elevation and a worsening of 
SHPT, in recent decades, the use of calcimimetics has been 
introduced.5
Calcimimetics bind with and activate the CaSRs, thereby 
increasing the response to serum calcium of the receptors on 
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the parathyroid glands that regulate parathyroid hormone 
secretion. Cinacalcet, therefore, acts by reducing PTH 
production by the parathyroid glands. In both placebo-
controlled and single-arm studies, the most commonly 
reported adverse reactions were nausea and vomiting, 
which were experienced by approximately 30% of patients6 
conditioning treatment discontinuation associated with the use 
of calcimimetics. Thus, as with most medicinal products, the 
efficacy of cinacalcet is poorer in patients who are not adherent 
with the prescribed treatment schedule.
Owing to the continuous stimulation of parathyroid glands, 
calcimimetic therapy must be continued over time, without 
interruption, adjusting the dose in line with PTH levels. The 
problem of treatment adherence, therefore, plays a crucial role 
in SHPT therapy.7
To evaluate different levels of therapeutic adherence to 
cinacalcet and their clinical and economic effects, we 
investigated the administrative database of the Regional Health 
Service of the Lombardy region (Italy) concerning CKD patients 
on renal replacement therapy (RRT). The main objective of this 
analysis was to describe the impact on hospitalisations and 
healthcare costs charged to the Italian National/Lombardy 
Regional Health Service (INHS/LRHS) of different treatment 
adherence to cinacalcet in SHPT patients on dialysis in the 
Lombardy region during 2011.
Methods
Data sources
For this retrospective observational study, data from the 
administrative database of the Lombardy region covering a 
total of 9.7 million residents were analysed. Healthcare services 
provided by the Italian National Health Service (specifically, 
drugs, hospitalisations, and diagnostic procedures) are 
systematically reported for each person in Local Health Services 
databases and subsequently pooled in regional databases for 
administrative assessments. The Italian National Health Service 
provides all citizens with free healthcare including hospital 
admissions, drugs, outpatient visits, and instrumental and 
biochemical tests and procedures through regional institutions. 
All citizens of Lombardy on dialysis in the period between 1 
January 2011 and 31 December 2011 were selected. All data of 
this study regarding patients, in accordance with applicable 
Italian privacy regulations, were extracted already anonymised 
from the administrative databases of Lombardy Region and 
analysed anonymously so that the informed consent was not 
applicable. All data regarding healthcare resource utilisation 
and costs charged to the LRHS were extracted for the period 
from 1 January 2009 to 31 December 2012.
Each identified patient was included in the dataset with an 
anonymous code (an untraceable code generated automatically 
during data extrapolation), in accordance with applicable Italian 
privacy regulations;8 this anonymous code is used to identify 
each patient in the individual section of the dataset. 
All drugs charged to the INHS was recorded, including those 
dispensed by both INHS facilities and local pharmacies. Data 
on hospital admissions charged to the INHS were recorded 
(admission and discharge dates, diagnosis, procedures 
performed during hospitalisation, and costs). Diagnostic 
procedures (laboratory tests, instrumental procedures, and 
ambulatory care) were recorded in terms of type, date, and 
costs; results were not recorded as they are not present in the 
Regional database.
Healthcare costs and perspective of the 
analysis
Unitary healthcare costs for hospitalisation and diagnostic 
procedures were extracted directly from the administrative 
database, and they coincide with the tariffs applied in the 
Lombardy region for the period considered; medication costs 
were also extrapolated directly from the database, and they 
represent the actual cost charged to the LRHS.
Indirect costs (not charged to the LRHS) and productivity losses 
were not considered, as they were outside the scope of this 
analysis. The analysis was conducted from the perspective of 
the LRHS.
Patient selection and classification
Of the patients on dialysis during 2011 in the Lombardy Region 
(identified using International Classification of Diseases, 9th 
Revision, Clinical Modification (ICD9-CM)9 codes 39.95 and 54.98), 
those already on dialysis in the first 6 months of 2009 who did 
not have acute kidney injury (ICD9-CM code 548) were selected.
In this population, SHPT patients were identified using the 
following criteria: hospitalisations with diagnosis of SHPT of 
renal origin (in or outside of the Lombardy Region, ICD9-CM 
code 588.81) and/or hospital admissions for parathyroidectomy 
(in or outside of the Lombardy Region, ICD9-CM code 06.81 
and/or 06.89) and/or prescriptions for cinacalcet (ATC code 
H05BX01, all reimbursed dosages, 30, 60, and 90 mg) and/or 
paricalcitol (ATC code H05BX02 all reimbursed dosages and 
formulations 1 µg, 2 µg, and 5 µg/mL). The SHPT population 
was described in terms of demographic characteristics and the 
presence of major comorbidities (cardiovascular (CV) disease, 
diabetes, and cancer). These comorbidities were identified as 
follows: CV disease by diagnosis at hospitalisation (ICD9-CM 
codes between 390 and 459 (diseases of the circulatory system) 
in or outside of the Lombardy Region), diabetes through the 
prescription of drugs with ATC code A10 (drugs for diabetes), 
and cancer through the prescription of drugs with ATC code 
L01 (antineoplastic drugs) and/or hospitalisation (in or outside 
of the Lombardy Region) with ICD9-CM code between 140 and 
239 (tumours). Other comorbidities used for the calculation 
for Mary Charlson index10 were also identified using ICD9-CM 
codes and the prescription of specific classes of drugs.11
Hospitalisation for all causes, due to CV disease, fractures 
(femur, hip, pelvis, and vertebral column), and sepsis were 
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identified using the diagnosis reported in the hospital 
discharge records and analysed to identify possible differences 
amongst the cinacalcet adherence tertiles. 
Evaluation of adherence to cinacalcet 
therapy
To evaluate adherence to cinacalcet treatment, SHPT patients 
treated in the observational period for at least 1 year were 
selected.
Adherence to treatment was calculated, on a patient-by-patient 
basis, as the percentage of treatable days (equal to the total 
number of dispensed tablets) out of the total number  
of days of treatment with the drug (calculated as the difference 
between the first and last date of cinacalcet treatment plus  
28 days, coinciding with the number of days covered by the 
last pack). The population was split into tertiles according to 
adherence. The selected population was observed, for the aims 
of adherence evaluation and cost analysis, over the period from 
1 January 2009 to 31 December 2012.
Statistical analysis
Proportions as the descriptive statistic for categorical variables 
and mean ± standard deviation (SD) or median, for continuous 
variables, were used. Kruskal−Wallis rank sum test was used to 
compare the distribution of the number of hospitalisations and 
costs between the three adherence tertiles. Differences in the 
demographic and clinical characteristics in patients amongst 
different tertiles were assessed through the Pearson Chi-
squared or the Fisher exact test for categorical variables and 
the Kruskal–Wallis rank sum test for continuous ones. R (version 
3.2.5) was used to perform data analysis.12
Results
In Lombardy Region, 8316 patients were on dialysis in 2011 
and 4791 were already on dialysis in the first 6 months of 2009 
(38.8% females; 86.3% treated with haemodialysis alone, 5.8% 
with peritoneal dialysis alone, and 7.8% with both).
According to the selection criteria, 1793 patients (37.4% of the 
population on stable dialysis) had SHPT; the average age of this 
population was 63.3 ± 14.4 years (median age 65.9), and 42.9% 
were females. In the population without SHPT, the average age 
was 70.2 ±13.2 years (median age 72.9) and 36.3% were females. 
The total annual healthcare cost covered by the LRHS in the 
SHPT population was €41,555 per patient, of which 68.7% for 
dialysis, 12.3% for hospitalisations, 8.9% for other diagnostic 
procedures and laboratory tests and 10.1% for drugs.
Of the SHPT population, 1373 patients were treated with 
cinacalcet and 994 (mean age 63.0 ± 65.3 years, females 
43.5%) received at least 12 months of treatment during the 
observation period. Median adherence to cinacalcet in the 
analysed population was 78.06% (48.5% of patients had an 
adherence greater than 80%). The first tertile of patients (n=333 
patients, mean age 62.5 ± 64.3 years, females 46.0%) had 
an adherence to cinacalcet treatment of <64.1%, the second 
(n=330 patients, mean age 63.3 ± 66.1 years, females 41.8%) 
had an adherence of between 64.1% and 91.5% and the third 
(n=331 patients, mean age 63.0 ± 64.2 years, females 42.6%) 
had an adherence of >91.5%. 
The average number of per patient hospitalisations for all 
causes, hospitalisations due to fractures, CV hospitalisations, 
and hospitalisations for sepsis in the various tertiles are 
reported in Table 1.
Between the third and first tertiles of adherence, there was a 
19.2% decrease in all-cause hospitalisations, a 37.1% decrease 
in hospitalisations for fractures, a 23.8% decrease in CV 
hospitalisations, and a 32.3% decrease in hospitalisations for 
sepsis. The difference amongst the tertiles was statistically 
significant for all-cause hospitalisations (p=0.01423), for CV 
hospitalisations (p=0.04025), and for hospitalisations for sepsis 
(p=0.01386) but was not significant for fractures (p=0.59422) 
(Figure 1), suggesting that there may be some correlation 
between a high level of cinacalcet adherence and the lower 
number of all-cause, CV, and sepsis hospitalisations.
We investigated the presence of differences in the demographic 
and clinical characteristics of patients amongst tertiles 
that could explain the decrease in the number of hospital 
admissions (other than adherence to cinacalcet) (Table 2).
As shown in Table 2, the characteristics of the populations 
in the three tertiles were similar except the percentage of 
patients treated with calcium-based phosphate binders, which 
significantly decreased with the increase in adherence to 
cinacalcet treatment (Pearson’s Chi-squared test, p=0.0417). 
Table 1. Average per-patient hospitalisations (4 years) by cinacalcet adherence tertile.
Cinacalcet 
adherence 
tertile
Average number of all-
cause hospitalisations 
per patient (4 years)
Average number of 
hospitalisations due to 
fractures per patient  
(4 years)
Average number 
of cardiovascular 
hospitalisations per 
patient (4 years)
Average number of 
hospitalisations for 
sepsis per patient  
(4 years)
First 5.438 0.07207 1.910 1.039
Second 5.103 0.06667 1.915 0.9091
Third 4.396 0.04532 1.456 0.7039
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Figure 1. Box plot of difference between tertiles in the per-patient number of hospitalisations.
 
Table 2. Demographic characteristics.
Variables First tertile 
(n=333)
Second tertile 
(n=330)
Third tertile 
(n=331)
p-value Type of test
Age (mean, years) 62.53 63.33 63.03 0.9801 Kruskal–Wallis rank 
sum test
Gender (%, females) 45.95 41.82 42.60 0.5244 Fisher’s exact test for 
count data
MCI (mean) 1.56 1.52 1.46 0.526 Kruskal–Wallis rank 
sum test
Type of dialysis (%)
 HD only 87.99 86.36 86.71 0.6183 Pearson’s Chi-squared 
test PD only 5.41 5.45 3.93
 HD+PD 6.61 8.18 9.37
Treatment with vitamin 
D (%)
28.23 30.91 31.72 0.591 Pearson’s Chi-squared 
test
Paricalcitol treatment (%) 38.74 36.36 42.30 0.2902 Pearson’s Chi-squared 
test
Non-calcium-based 
phosphate binders (%)
84.68 87.27 83.69 0.4071 Pearson’s Chi-squared 
test
Calcium-based 
phosphate binders (%)
36.94 32.12 27.79 0.04174 Pearson’s Chi-squared 
test
RAS inhibitors (%) 79.88 84.55 82.48 0.2883 Pearson’s Chi-squared 
test
ESA (%) 22.82 21.82 23.26 0.9017 Pearson’s Chi-squared 
test
ESA, erythropoietic stimulating agents; HD, haemodialysis, MCI, Mary Charlson index; PD, peritoneal dialysis;  
RAAS, renin–angiotensin–aldosterone system.
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Figure 2. Distribution of annual per-patient cost by tertile.
First tertile Second tertile Third tertile
Diagnostic and therapeutic procedures € 34,222 32,483 33,463
Hospitalizations € 5321 5255 4199
Cinacalcet € 1037 2209 3330
Territorial drugs € 1956 2338 2455
Drugs distributed directly by NHS structures € 665 514 785
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Table 3. Average per-patient hospitalisation costs (4 years) by cinacalcet adherence tertile.
Cinacalcet 
adherence tertile
Per-patient cost of  
all-cause 
hospitalisations  
(4 years) 
Per-patient cost of 
hospitalisations for 
fractures (4 years) 
Per-patient cost 
of cardiovascular 
hospitalisations (4 
years) 
Per-patient cost of 
hospitalisations for 
sepsis (4 years) 
First €21,283 €476 €9005 €5383
Second €21,020 €442 €9591 €4133
Third €16,797 €249 €7264 €3121
Although it is not statistically significant, a higher percentage 
of use of VDRs activators (vitamin D and paricalcitol) in the third 
tertile than in the first can be observed. The average annual 
per-patient cost was €43,201 in the first tertile, €42,800 in the 
second, and €44,232 in the third (Figure 2).
Diagnostic and therapeutic procedures (including dialysis) 
represented by far the major cost driver in all tertiles. 
Hospitalisation costs accounted for 12.3% of total costs in 
the first and second tertiles and decreased to 9.5% in the 
third. Conversely, drug costs (excluding cinacalcet) increased 
from 6.1% of total costs in the first tertile to 7.3% in the third. 
Cinacalcet costs accounted for 2.4% of total costs in the first 
tertile and increased to 7.5% in the third; whereas, in relation to 
total medication costs, cinacalcet accounted for 28% in the first 
tertile, 44% in the second tertile, and 51% in the third. We also 
analysed the differences amongst adherence tertiles in terms of 
the costs of hospitalisation for all causes, CV disease, fractures, 
and sepsis (Table 3).
Differences were statistically significant for all-cause 
hospitalisation costs (p=0.0127) and for sepsis (p=0.01109). The 
decrease in costs between the third and first adherence tertiles 
was 21.1% (−€4486) for all-cause hospitalisations, 47.7% for 
hospitalisations for fractures, 19.3% for CV hospitalisations, and 
42.0% for hospitalisations for sepsis.
Discussion and conclusions
In this retrospective study based on the data reported in 
the LRHS, amongst the 994 patients chronically treated with 
cinacalcet, the first tertile had an adherence to cinacalcet 
treatment lower than 64.1% and the third had an adherence of 
over 91.5%. Patients in the third adherence tertile experienced 
significantly fewer all causes and cardiovascular hospitalisations 
than those in the first tertile, fewer fractures, and sepsis. The 
reduction in hospitalisation cost almost completely offsets the 
increased cost of cinacalcet in this group.
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−19% for all causes, −37% for fractures, −24% for cardiovascular 
diseases and −38% for sepsis with statistical significance for 
hospital admissions for all causes, CV disease and sepsis, 
suggesting a relationship between therapeutic adherence 
and hospitalisations; those decreases have a consequent 
effect on reduction of hospitalisation costs from the first to 
the third tertile. The majority of these data are supported 
by several observational and experimental studies that had 
reported a relationship between cinacalcet use and all-cause 
and cardiovascular-related hospitalisations.23–26 The limited 
information available in the literature regarding the relationship 
between cinacalcet use and infection-related hospitalisations is 
largely controversial; the results of one meta-analysis27 indicated 
that the cinacalcet use increased the upper respiratory tract 
infections, whereas in one more recent study28 the authors did 
not observe any increase in infection-related hospitalisations, 
rather, in the patient group with the lowest PTH levels, there 
was a significant correlation with a lower incidence of infection-
related hospitalisations. Although no clear explanation of the 
positive effect of better adherence to cinacalcet therapy and 
reductions in infection-related hospitalisation is given in any 
published paper, one explanation could be a more careful use 
of vitamin D receptor activator (VDRA) in compliant patients, 
as this seems to have occurred in third-tertile patients, most 
probably due to hypocalcaemia secondary to parathyroid 
inhibition (Figure 3). Although this hypothesis may be attractive, 
its demonstration based on the information contained in the 
analysed database is not possible as Ca, P, and PTH values are 
not included. From a clinical point of view, the fact that fewer 
infection-related hospitalisations were observed amongst 
cinacalcet-adherent patients is an important point that deserves 
further investigation, given the high risk of infection amongst 
dialysis patients. To exclude a well-known role of central 
venous catheters (cvc) in influencing infectious risk in dialysis 
patients,29 we analysed the percentage distribution of cvc 
carriers in tertiles without finding any significant difference. The 
percentage decrease for hospital admissions for all causes and 
sepsis reached statistical significance (p=0.0127 and p=0.01109, 
respectively). These results show a non-negligible relationship 
between therapeutic adherence, clinical outcomes, and costs.
The main strength of this analysis is the data integrity 
achieved by analysing administrative databases, because 
they automatically record all the events that take place for 
every citizen living in the region with the main purpose of an 
economic assessment, which makes them very detailed and 
precise. However, this characteristic can also be considered 
a weakness, as the data have no clinical or epidemiological 
purpose and lack certain important clinical and biological 
parameters. Furthermore, this reflects real-world practice at 
the population level.33 Unfortunately, although they are able to 
provide accurate and reliable economic assessments, studies 
based on the analysis of this type of data are unable to provide 
solutions to clinical problems. Unlike prospective randomised 
clinical trials, the gold standard of medical evidence, the use of 
‘real-world’ data may be particularly useful when considering 
According to the selection criteria implemented on the 
database, 37.4% of patients had SHPT, a value that is not 
significantly different to that observed in the DOPPS data from 
Italian dialysis centres.13 The use of calcimimetics (cinacalcet 
HCl) is particularly effective in reducing plasma PTH levels, and 
consequently Ca and P in patients with SHPT on dialysis.6,14 Even 
in the approval phase, a number of gastrointestinal side effects 
emerged with a non-negligible frequency and they could be the 
cause of the high frequency of discontinuation of the treatment 
within 6–12 months from the start of therapy, and similar 
frequency of restart.15. These side effects increase with the dose 
administered and could be associated with the specific activity 
exerted on the gastrointestinal CaSRs. Cinacalcet is nevertheless 
extensively used in CKD-5D patients due to both its efficacy and 
the high number of SHPT patients on dialysis and is likely to be 
considered the most effective treatment for SHPT, even though 
this statement was not uniformly shared by the working group 
of recent KDIGO due to the negative primary endpoints of the 
EVOLVE study,16,17 In consideration of the influence of treatment 
adherence on the outcome also in RCTs, it is important to 
underline how the post hoc analysis of the EVOLVE study, 
made not on the basis of intention to treat (ITT) but on the real 
adherence to treatment, modify the significance of the results 
related to mortality and major cardiovascular events.18
The therapeutic adherence explored by comparing the time 
covered by medical prescription of the drug (also considering 
regimen changes) and the time elapsing between prescriptions 
showed that a large proportion of subjects had less than a 
reasonable level of therapeutic adherence, making it difficult 
to assess the impact of therapeutic adherence on expected 
outcomes. To investigate the role of therapeutic adherence in 
determining costs and clinical outcomes, the population was 
divided in tertiles: patients belonging to the first tertile had a 
low adherence (<64%), the second >64% but <91%, and the 
third had an adherence of >91%. Thirty-three percent of the 
patients considered achieved the highest level of adherence, 
in line with the findings of a study involving more than 4000 
patients on dialysis that showed that 28% of patients had a high 
level of adherence 1 year after the start of the treatment.19 This 
low cinacalcet adherence rate is not surprising, is supported by 
numerous other reports,20–22 and may be explained by several 
factors including that CKD-MBD is not generally perceived by 
dialysis patients as a disease to be cured, as it produces little or 
no symptoms regardless of therapeutic adherence, until a late 
stage; whereas, the medicinal products prescribed have side 
effects (cinacalcet) or involve taking a large number of tablets 
(phosphate binders). Hospital admissions have been considered 
as the most reliable and safe clinical outcome, in absence in the 
administrative database of the recording of causes of death but 
only of their date. Frequency of hospitalisations for all causes, 
cardiovascular disease, sepsis, and fractures were analysed by 
tertiles. The data distribution and dispersion described in the 
box plot in Figure 1 showed a gradual decrease in the number 
of hospital admissions during the observation period for all 
the variables considered from the first to the third tertile of 
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with a very limited mean variation of −4.6%.34 Regarding the 
most relevant changes in drugs prices, the cinacalcet price did 
not change whilst the paricalcitol price decreased by 50% for 
the generic formulations with an impact on total per patient 
yearly cost of less than 2%. These variations do not affect 
significantly our results.
Finally, administrative databases do not contain information 
regarding the impact of the decrease in hospitalisations on 
the general expenses incurred for the organisation of Regional 
Health Services, or the direct and indirect benefits on patient 
well-being that were not part of the purpose of this study. 
the use of a drug and its level of therapeutic adherence in a 
specific group of subjects. 
The major limitation of this study is linked to the structure 
of the administrative databases, in which the clinical and 
laboratory data are not collected; consequently, the effects of 
therapies should be evaluated thorough surrogate endpoints 
(in our case, the frequency of hospitalisations).
The other major limitation is that the data refer to years 2009–
2013: this period still provides reliable data even if the national 
reimbursement tariffs for hospitalisations changed in 2013 but 
Figure 3. Hypothesis for cinacalcet and decrease in infection-related 
hospitalisations.28,30,31,32
1,25-OH2D
PTH
SHPT
Infections risk
Innate immunity
Adaptative Immunity
Ca++
PTH
Responders
(adherent)
Non-responders
(non-adherent)
SHPT worsening
VDR activators:
1,25-OH2D
Paricalcitrol
VDRs
activation
AMPs
Cathelicidin
Β Defensins
NFk-B DNA
transcription
Restoring
innate
immunity
Possible
infection
reduction
CKD5D
Calcimimetics use
According to Asada’s hypothesis, SHPT patients with the highest adherence to cinacalcet 
therapy who achieve the objective of reducing PTH levels to almost normal values 
would also have a marked reduction in calcium levels. Hypocalcaemia leads to increased 
administration of VDR activators. Activated VDRs residing on immune cells increase 
the production of antimicrobial peptides, thus improving the level of innate depressed 
immunity. 1,25-OH2D: 1,25-dihydroxyvitamin D3; AMPs: antimicrobial peptides; NFk-B: 
protein complex-transcription factor; Dotted lines: hypothetical pathways.
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